Sugi Predict

Sugi Predict / Compounds / SCHEMBL597614

SCHEMBL597614

SCHEMBL597614

O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2cccc([AsH2])c21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 10/20 0.63
▸ MAPT P10636 4/20 0.63
▸ MEN1 O00255 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ HPGD P15428 2/20 0.63
▸ HTT P42858 2/20 0.63
▸ TDP1 Q9NUW8 2/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ RECQL P46063 1/20 0.63
▸ BLM P54132 1/20 0.63
▸ SMAD3 P84022 1/20 0.63
▸ PRMT1 Q99873 1/20 0.63
▸ ACE2 Q9BYF1 1/20 0.63
▸ ALDH1A1 P00352 3/20 0.60
▸ ALOX12 P18054 2/20 0.60
▸ ALOX15 P16050 2/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ BRCA1 P38398 1/20 0.60
▸ LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6662140 0.86 FTO (0.74) FTOMAPTMEN1KMT2AHPGD
SCHEMBL3189664 0.86 FTO (0.66) FTOMAPTMEN1KMT2AHPGD
SCHEMBL3459139 0.85 FTO (0.64) FTOMAPTMEN1KMT2AHPGD
SCHEMBL4519856 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL1908131 0.84 HPGD (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL5052755 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL5475534 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL2360878 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL6247181 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD
SCHEMBL1682613 0.84 FTO (0.63) FTOMAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183781-A1 METHOD FOR THE GENOTYPING OF MOUSE STRAINS GVG GENETIC MONITORING GMBH (DE) 2023-06-15 — — US disclosed
EP-3631014-A1 METHOD FOR THE GENOTYPING OF MOUSE STRAINS GVG Genetic Monitoring GmbH (DE) 2020-04-08 — — EP disclosed
US-20140081007-A1 Methods For The Detection, Analysis And Isolation of Nascent Proteins AMBERGEN, INC. (US) 2014-03-20 — — US disclosed
US-8278045-B2 Methods for the detection, analysis and isolation of nascent proteins AMBERGEN, INC. (US) 2012-10-02 — — US disclosed
US-8114587-B2 Methods for the detection of colorectal cancer AMBERGEN, INC. (US) 2012-02-14 — — US disclosed
US-20110250609-A1 Methods For The Detection, Analysis And Isolation Of Nascent Proteins AMBERGEN, INC. 2011-10-13 — — US disclosed
EP-1767629-B1 Methods for the detection, analysis and isolation of nascent proteins AMBERGEN INC (US) 2011-04-20 — — EP disclosed
US-7897335-B2 Detection of preferential proteins in sample; obtain sample nucleotide sequences, dilute, amplify sequences, translate, test for proteins AMBERGEN, INC. (US) 2011-03-01 — — US disclosed
US-20110045991-A1 Methods for the Detection of Colorectal Cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-02-24 — — US disclosed
EP-1581797-B1 METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS AMBERGEN INC (US) 2009-09-23 — — EP disclosed
US-20040209317-A1 Methods and compositions for peptide and protein labeling MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2004-10-21 — — US disclosed
WO-2004063714-A2 METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS AMBERGEN, INC. (US) 2004-07-29 — — WO disclosed
US-20040014071-A1 Methods for the detection, analysis and isolation of nascent proteins AMBERGEN, INC. 2004-01-22 — — US disclosed
US-20030190643-A1 Sequencing by mass spectrometry THE TRUSTEES OF BOSTON UNIVERSITY 2003-10-09 — — US disclosed
US-20030092031-A1 Methods for the detection, analysis and isolation of nascent proteins AMBERGEN, INC. 2003-05-15 — — US disclosed
US-20020132248-A1 N-terminal and C-terminal markers in nascent proteins AMBERGEN, INC. 2002-09-19 — — US disclosed
EP-1210449-A1 METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS Ambergen, Inc. (US) 2002-06-05 — — EP disclosed
US-6306628-B1 PROVIDING TRNA MOLECULE CHARGED WITH AMINO ACID AND FLUOROPHORE MARKER, REACTING TRNA MOLECULE WITH MARKER TO CREATE TRNA/MARKER CONJUGATE WHEREIN AMINO ACID OF TRNA OF TRNA/MARKER CONJUGATE IS COVALENTLY BONDED TO MARKER AMBERGEN, INCORPORATED 2001-10-23 — — US disclosed
US-6303337-B1 ADDING MISAMINOACYLATED INITIATOR TRNA THAT RECOGNIZES ONLY THE FIRST AUG CODON TO TRANSLATION SYSTEM; GENE EXPRESSION, EVALUATION; GENETIC ENGINEERING AMBER GEN. INC. 2001-10-16 — — US disclosed
WO-2001014578-A1 METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS AMBERGEN, INC. (US) 2001-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014071-A1 Methods for the detection, analysis and isolation of nascent proteins EIF4A1, NOP2, EIF4A3 FTO 1209/4885MAPT 4301/4885MEN1 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback